De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Precigen Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Precigen is de winst gegroeid met een gemiddeld jaarlijks percentage van 25.5%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.7%. De inkomsten zijn gedaald met een gemiddelde van 50.3% per jaar.

Belangrijke informatie

25.5%

Groei van de winst

38.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-50.3%
Rendement op eigen vermogen	-313.6%
Nettomarge	-3,084.6%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Opbrengsten en kosten

Hoe Precigen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:PGEN Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	4	-135	40
31 Mar 24	5	-97	39
31 Dec 23	6	-96	40
30 Sep 23	7	-85	42
30 Jun 23	22	-73	43
31 Mar 23	23	-79	46
31 Dec 22	27	-80	48
30 Sep 22	29	-84	48
30 Jun 22	15	-103	49
31 Mar 22	16	-108	51
31 Dec 21	14	-111	52
30 Sep 21	30	-124	71
30 Jun 21	50	-125	82
31 Mar 21	77	-110	85
31 Dec 20	32	-104	73
30 Sep 20	101	-100	88
30 Jun 20	96	-122	88
31 Mar 20	98	-138	89
31 Dec 19	91	-169	99
30 Sep 19	108	-373	85
30 Jun 19	122	-381	102
31 Mar 19	134	-414	117
31 Dec 18	151	-375	125
30 Sep 18	194	-196	148
30 Jun 18	208	-179	148
31 Mar 18	217	-132	153
31 Dec 17	219	-71	130
30 Sep 17	200	-134	148
30 Jun 17	203	-123	143
31 Mar 17	201	-154	134
31 Dec 16	191	-187	138
30 Sep 16	186	-175	137
30 Jun 16	191	-184	125
31 Mar 16	183	-176	118
31 Dec 15	174	-84	107
30 Sep 15	163	-33	92
30 Jun 15	131	-47	85
31 Mar 15	98	-59	76
31 Dec 14	72	-82	63
30 Sep 14	48	-113	53
30 Jun 14	33	-52	46
31 Mar 14	28	-11	39
31 Dec 13	24	-57	33

Kwaliteitswinsten: PGEN is momenteel verliesgevend.

Groeiende winstmarge: PGEN is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: PGEN is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 25.5% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van PGEN over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: PGEN is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: PGEN heeft een negatief Return on Equity ( -313.6% ), omdat het momenteel verliesgevend is.

Precigen Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Recent updates

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront